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Novelty and impact: The role of nitric oxide in cancer is contentious and has been 
attributed both tumour inhibitory and promoting properties. We show that tumour-derived 
inducible nitric oxide synthase is an important mediator of tumour growth and vessel 
maturation, hence a promising therapeutic target. Moreover, the combination of intrinsic and 
extrinsic susceptibility magnetic resonance imaging provides a non-invasive biomarker of 
tumour vascular function, hence may aid assessment of response to anti-vascular therapies, 
such as iNOS inhibitors.  
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Abstract 
Nitric oxide (NO) is a free radical signalling molecule involved in various physiological and 
pathological processes, including cancer. Both tumouricidal and tumour promoting effects 
have been attributed to NO, making its role in cancer biology controversial and unclear. To 
investigate the specific role of tumour-derived NO in vascular development, C6 glioma cells 
were genetically modified to include a doxycycline regulated gene expression system that 
controls the expression of an antisense RNA to inducible nitric oxide synthase (iNOS) in 
order to manipulate endogenous iNOS expression. Xenografts of these cells were 
propagated in the presence or absence of doxycycline. Susceptibility magnetic resonance 
imaging (MRI), initially with a carbogen (95% O2 / 5% CO2) breathing challenge and 
subsequently an intravascular blood pool contrast agent, was used to assess 
haemodynamic vasculature (∆R2*) and fractional blood volume (fBV), and correlated with 
histopathological assessment of tumour vascular density, maturation and function. Inhibition 
of NO production in C6 gliomas led to significant growth delay and inhibition of vessel 
maturation. Parametric fBV maps were used to identify vascularised regions, from which the 
carbogen-induced ∆R2* was measured and found to be positively correlated with vessel 
maturation, quantified ex vivo using fluorescence microscopy for endothelial and 
perivascular cell staining. These data suggest that tumour-derived iNOS is an important 
mediator of tumour growth and vessel maturation, hence a promising target for anti-vascular 
cancer therapies. The combination of ∆R2* response to carbogen and fBV MRI can provide 
a marker of tumour vessel maturation that could be applied to non-invasively monitor 
treatment response to iNOS inhibitors.  
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Introduction 
Nitric oxide (NO) is an important pleiotropic signalling molecule involved in physiological and 
pathophysiological processes, and has been detected in a variety of human tumours, 
including colon, breast, prostate, and brain.1, 2 The effect of NO in tumours depends upon 
the exposure to NO in terms of duration and concentration, the intrinsic sensitivity of cells to 
NO, and the expression, activity and temporal distribution of the three nitric oxide synthases 
(NOS): neuronal (nNOS or NOS1), inducible (iNOS or NOS2), and endothelial (eNOS or 
NOS3) that catalyse the synthesis of NO from L-arginine.2 Tumour cells express iNOS and 
in some cases nNOS and eNOS, tumour-associated immune cells and stromal fibroblasts 
express iNOS, and vascular endothelial cells mainly express eNOS.3  
The effect of NO in cancer has been the cause of intense debate due to its dichotomous 
nature, with studies indicating that NO has both tumour inhibitory and promoting properties.4, 
5 iNOS has also been implicated in tumour progression and angiogenesis. In human 
cancers, such as colon adenocarcinomas,6 and central nervous system cancers,7 increased 
iNOS expression and activity was positively correlated with vascularisation and higher 
tumour grade. In human gliomas, high iNOS expression was inversely correlated with patient 
survival irrespective of the tumour grade, suggesting that iNOS expression is a negative 
prognostic factor for glioma patients.8 Overexpression of iNOS in human colon 
adenocarcinoma xenografts increased tumour growth and angiogenesis,9, 10 whereas iNOS 
overexpression in melanoma and prostate tumours induced apoptosis and delayed tumour 
growth.11, 12  
Manipulation of NO can be achieved pharmacologically with NO donors13 or NOS 
inhibitors,14 or genetically such as in iNOS knockout mice.15 NO inhibition by selective or 
non-selective NOS inhibitors can reduce tumour growth and have anti-angiogenic effects.16-
18 Moreover, the NOS inhibitor N-nitro-L-arginine (L-NNA) elicited tumour anti-vascular 
effects in a phase I clinical trial.19 However, pharmacological NOS inhibition could lead to 
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adverse systemic effects, including hypertension, sinus bradycardia and palpitation.19 
Studies with NO donors suggest a concentration-dependent role of NO, whereby low 
concentrations of NO donors inhibit tumour growth and angiogenesis, whereas high 
concentrations reduce the anti-tumour response due to interference with the host physiology 
and can affect not only tumour- but also stromal-derived NO.13 A more refined approach is 
afforded by genetic manipulation of tumour cells in which iNOS is either overexpressed10, 20 
or suppressed,21, 22 enabling the specific investigation of the effects of tumour cell-derived 
NO.  
In the present study, a novel doxycycline inducible iNOS expression system was engineered  
to robustly interrogate the role of exclusively tumour-derived iNOS on tumour growth and 
vascular development in subcutaneous C6 gliomas using in vivo MRI and ex vivo 
histopathological analysis.   
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Materials and Methods 
Cell culture  
C6 rat glioma cells (European Collection of Cell Cultures, Salisbury, UK) were maintained in 
Nutrient Ham’s F-10 (Sigma-Aldrich, Dorset, UK) medium supplemented with 2 mM L-
glutamine, 100 U/ml penicillin, 0.2 mg/ml streptomycin and 10% (v/v) fetal bovine serum.  
To achieve intrinsic, inducible inhibition of tumour-derived iNOS, C6 cells were engineered to 
include an antisense iNOS cDNA sequence combined with a tetracycline inducible system 
(pTet Off), where gene expression is controlled by doxycycline, the water soluble derivative 
of tetracycline (Supplementary Methods). Stably transfected cells (designated C6 pTet-off 
asiNOS) were grown in the presence or absence of 2 µg/ml doxycycline.  
 
Nitric oxide production 
Cells were stimulated with cytokines (10 ng/ ml TNF-α, 1000 U/ml IFN-γ) and 5µg/ml LPS. 
Nitrite production provided a proxy measure of NO synthesis determined using the Griess 
reaction.23 To detect total NO in tumour homogenates, nitrate was reduced to nitrite using 
vanadium chloride and the total nitrate plus nitrite (NOx) determined using the Griess 
reaction.24 
 
Western blot analysis 
The protein concentration of cell lysates or tumour homogenates was determined using the 
Bradford assay25 and equal amounts of protein were analysed by SDS–PAGE. iNOS 
expression was detected using a rabbit polyclonal anti-mouse iNOS antibody (M-19) (sc-
650, Santa Cruz, Heidelberg, Germany), a goat anti-rabbit horseradish peroxidase (HRP) 
(Dako Ltd., Cambridgeshire, UK), and an Immobilon Western Chemiluminescent HRP 
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substrate (GE Healthcare, Chalfont St. Giles, UK). A polyclonal anti-α-actin antibody (Sigma-
Aldrich) was used to verify equal protein loading. 
 
Animals and Tumours 
Experiments were performed in accordance with the UK Home Office Scientific Procedures 
Act 1986. Female (7 - 8 weeks old) NCr nude mice were injected subcutaneously in the 
flanks with 2 x 106 cells in 0.1 ml phosphate-buffered saline (PBS). Tumour size was 
measured using callipers and tumour volume calculated assuming an ellipsoid shape, using: 
(π/6) × L × W × D, where L, W and D are the largest orthogonal dimensions of the ellipsoid. 
Animals were given drinking water containing 5% (w/v) sucrose with or without 0.2 mg/ml 
doxycycline. Doxycycline administration started five days prior to tumour cells injection and 
was maintained until the end of the experiment. The drinking water containing sucrose ± 
doxycycline was changed every other day. Henceforth, tumours grown without doxycycline 
will be referred to as NO- tumours and tumours grown with doxycycline as NO+ tumours. 
 
Magnetic resonance imaging  
Mice bearing size-matched tumours grown in the presence or absence of doxycycline were 
anaesthetised with a 10 ml/kg intraperitoneal injection of Hypnorm (0.315 mg/ml fentanyl 
citrate plus 10 mg/ml fluanisone; Janssen Pharmaceutical, Wantage, UK), Hypnovel (5 
mg/ml midazolam; Roche, West Sussex, UK) and water (1:1:2). A lateral tail vein was then 
cannulated with a heparinised 27-gauge butterfly catheter for contrast agent administration 
during MRI. The mouse was positioned so the tumour hung within a three-turn 25 mm 
diameter surface coil for MRI using a 4.7 T Varian Unity INOVA horizontal small-bore 
imaging system.  A nose cone was positioned for breathing gas delivery, and heated air 
blown through the magnet bore used to maintain the mouse core temperature at 37°C. 
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Blood oxygen saturation was monitored using a MouseOx Pulse Oximeter (Braintree 
Scientific, Massachusetts, US).  
T2-weighted spin echo images were acquired from seven axial 1 mm thick slices positioned 
across the whole tumour, using a repetition time (TR) of 1500 ms, an echo time (TE) of 30 
ms, and a 128 x 128 matrix over a 2.56 cm field of view. Susceptibility MRI was used to 
quantify changes in the tumour MRI transverse relaxation rate R2* (s
-1) caused by 
perturbations in the paramagnetic deoxyhaemoglobin (dHb) content in the blood vessels. 
Carbogen (95% O2 / 5% CO2) breathing, a hypercapnic hyperoxia challenge, was used to 
increase blood oxygenation, and to probe for localised vascular smooth muscle dilation via 
blood flow induced oxygenation changes, and hence to assess vessel function and 
maturation.26-28 Multi-gradient echo (MGRE) images were acquired from seven slices with 
TR of 450 ms, TE of 7 to 56 ms, an echo spacing of 7 ms and flip angle (α) of 45°. MGRE 
images were acquired during air and then, following a 5 minute transition period, during 
carbogen breathing.  
Air breathing was then resumed and once the mouse blood oxygen saturation had recovered 
to initial air-breathing levels, tumour fractional blood volume (fBV, %) was quantified by 
susceptibility contrast MRI, utilising ultrasmall superparamagnetic iron oxide (USPIO) 
particles as a blood pool contrast agent. USPIO particles create magnetic susceptibility 
variations close to blood vessels, increasing R2* of water in the surrounding tissue.  Their 
long intravascular half-life enables steady-state measurements of tumour R2* to be made to 
determine fBV.29  MGRE images were acquired prior to and 5 minutes after intravenous 
injection of 5.2 mgFe/kg of the USPIO contrast agent ferumoxtran (Guerbet S.A., Villepinte, 
France).  
 
MRI data analysis 
R2* maps were calculated on a voxel-by-voxel basis from MGRE image data using ImageJ and 
Matlab. Average apparent R2* relaxation rates were calculated for each slice for a region of 
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interest (ROI), defined from the associated T2-weighted image, encompassing the whole 
tumour but excluding the surrounding skin and muscle. Carbogen-induced changes in R2* 
(∆R2*CB = R2*carbogen - R2*air) were determined over the whole tumour. Tumour fBV was 
determined over the same ROI from the increase in R2* (∆R2*USPIO = R2*post-USPIO - R2*pre-USPIO) 
caused by the USPIO particles.29   
To reduce contributions from noise and from averaging over necrotic and poorly perfused 
tumour regions in the global measurement of carbogen-induced ∆R2*, a retrospective 
analysis of the intrinsic susceptibility data was performed using the calculated fBV. The 
median fBV from all tumours was applied as a threshold to define vascularised regions in the 
∆R2*CB maps, and hence measure the carbogen-induced ∆R2* that relates to vascular 
tumour tissue. 
 
Immunohistochemistry and fluorescence microscopy 
Immediately following MRI, mice were administered intraperitoneally with 60 mg/kg of the 
hypoxia marker pimonidazole hydrochloride (Hypoxyprobe, Burlington, MA, USA) in PBS. 
After 45 min mice were injected intravenously through a lateral tail vein with 15 mg/kg of the 
perfusion marker Hoechst 33342 (Sigma-Aldrich, Dorset, UK) in PBS. Tumours were 
excised after 1 min and snap-frozen. For each tumour, three acetone-fixed cryosections (10 
µm) were visualized for Hoechst 33342 uptake by fluorescence microscopy at 365 nm using 
a motorized scanning stage (Prior Scientific Instruments, Cambridge, UK) attached to a 
BX51 microscope (Olympus Optical, London, UK) driven by CellP (Soft Imaging System, 
Munster, Germany) to record composite digital images of whole tumour sections. The same 
sections were then processed for the formation of pimonidazole adducts, using 
Hypoxyprobe-1 plus FITC-conjugated mouse monoclonal antibody (1/1000) and recorded at 
450-490 nm using the same stage coordinates. To assess endothelial and perivascular cell 
content, additional sections were stained with rat monoclonal anti-mouse CD31 antibody 
[MEC 7.46] (1/50, ab7388, Abcam, Cambridge, UK), biotinylated goat anti-mouse 
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immunoglobulin (IgG) (1/300, Vector Laboratories, Peterborough, UK) and Fluorescein 
Avidin D (1/250, Vector Laboratories), and subsequently, with rabbit polyclonal antibody 
against smooth muscle actin (α-SMA, 1/200, ab5694, Abcam) and Alexa-Fluor 546 goat anti-
rabbit secondary antibody (1/1000, Invitrogen, Paisley, UK). Non-immune mouse and rabbit 
IgG antibodies were used in the same concentration with CD31 and α-SMA antibodies 
respectively, to be used as negative isotype controls. Fluorescein Avidin D was detected at 
495-515 nm and Alexa-Fluor 546 at 556-573 nm and composite images were recorded.  
Post-processing was performed on composite digital images using CellP or ImageJ software 
30. ROIs encompassing the whole tumour sections were defined and fluorescent particles 
detected above a constant across all sections colour threshold, which was higher than 
background fluorescence as defined from the negative control stained tumour sections. The 
area of the tumour section with Hoechst 33342, pimonidazole adduct, CD31 or α-SMA 
fluorescence was determined and expressed as a percentage of the whole tumour section, 
and for each tumour the average across three slices was determined.  
 
Haematoxylin and eosin staining 
Frozen tumour sections were stained with haematoxylin and eosin (H&E) and visualized 
under light microscopy using the same system as for the detection of fluorescence. 
Composite images of whole tumour sections were recorded and ROIs drawn around all 
necrotic foci using ImageJ. For each tumour, necrosis was expressed as a percentage 
averaged across three slices. 
 
VEGF ELISA 
Culture medium was collected when confluent from 3cm dishes 72 h after seeding and 
analysed for VEGF expression using a rat VEGF ELISA kit (PeproTech, London, UK) 
according to manufacturer’s instructions. VEGF expression was also measured in tumour 
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homogenates. Values were normalized to the protein concentration of cells or tumours, 
determined using the Bradford assay.25 
 
Statistical analysis 
Results are presented as mean ± 1 standard error of the mean (SEM) with significance 
testing at a 5% confidence level. Student’s unpaired t-test was used to compare two groups, 
whereas repeated measures ANOVA with Bonferroni’s Multiple Comparison post-test was 
used to compare multiple groups. 
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Results 
Generation of a switchable system for iNOS expression in C6 glioma cells 
The basal expression of iNOS and the synthesis of NO by the C6 pTet-off asiNOS cells in 
the presence or absence of doxycycline were barely detectable. Stimulation of C6 pTet-off 
asiNOS with cytokines and LPS for two days in the presence of doxycycline (designated 
NO+) resulted in the increased expression of iNOS and a two-fold increase in the production 
of NO as determined by nitrite. In the absence of doxycycline (designated NO-), an antisense 
iNOS RNA was expressed, which blocked the stimulated expression of iNOS and inhibited 
the production of NO (Figure 1). Reduced iNOS expression did not affect the growth 
properties of cells in vitro. Growth rates of the cells, determined by measuring cell 
proliferation and death over 5 days, were the same in the presence or absence of 
doxycycline (Supplementary Figure 1).  
 
In vivo investigation of NO manipulation on tumour growth 
Endogenous iNOS protein was expressed in C6 pTet-off asiNOS tumours grown in animals 
drinking doxycycline. However, iNOS expression was limited in tumours grown without 
doxycycline (Figure 2A). Decreased iNOS expression led to a reduction in NO production. 
Nitrite production was similar in tumours grown in the presence or absence of doxycycline 
(data not shown). However, nitrite is an unstable product and can be further oxidized to 
nitrate. NOx (nitrite plus nitrate) production was reduced (3.5-fold) in NO- tumours compared 
with NO+ tumours (Figure 2B). NO- tumours had significantly reduced growth rates 
compared with the NO+ tumours. The mean tumour volume at 46 days post-inoculation was 
approximately half in the absence of NO compared with its presence (Figure 2C).  
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Effects of NO down-regulation on tumour vascular development   
Mice bearing size-matched tumours were selected for MRI. There was no significant 
difference in mean tumour volume between NO+ (632 ± 192 mm3) and NO- (554 ± 65 mm3) 
cohorts at the time of imaging, which was 46 ± 4 days (post-inoculation) for the NO+ and 54 
± 1 days for the NO- tumours. Representative T2-weighted images and parametric maps of 
baseline R2*, fBV and carbogen-induced ∆R2* from both tumours cohorts are shown in 
Figure 3A. No significant differences were found between the R2* determined during air 
breathing prior to carbogen challenge (R2*air), and those prior to administration of USPIO 
particles (R2*pre-USPIO). All mice responded to carbogen breathing with an increase in blood 
oxygen saturation of 3.9 ± 2.5% in the NO- group and 5.2 ± 1.8% in the NO+ group. 
Carbogen induced a negligible change in R2* averaged over the whole tumour in both 
cohorts. NO- tumours exhibited a significantly higher overall fBV compared with the NO+ 
tumours (Figure 3B). For tumour regions selected with vascular volume greater than the 
overall median, there was no difference in fBV between the two cohorts (Figure 3C). 
However, for these regions the intrinsic susceptibility MRI data revealed a significantly 
greater reduction in R2* with carbogen breathing in NO
+ compared with NO-tumours (Figure 
3D).  Thus, a smaller ∆R2*CB response was observed in the NO
- tumours in regions with 
similar fBV to NO+ tumours.  
Representative histological images from both tumour groups are shown in Figure 4. The 
Hoechst 33342-perfused area was significantly higher in the NO- tumours compared with 
NO+ tumours (Figure 5A). The degree of hypoxia was similar between the two groups 
(Figure 5B). The extent of necrosis was significantly higher in the NO+ compared with the 
NO- tumours (Figure 4B and 5C). The endothelial cell content of NO- tumours was 
significantly higher than in tumours with NO (Figure 5D). Conversely, the perivascular cell 
content was almost double in NO+  compared with NO- tumours (Figure 5E). The fraction of 
mature vessels,  quantified using the ratio of α-SMA stained area versus the CD31 stained 
area, was significantly higher in NO+ compared with NO- tumours (Figure 5F).  
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Effect of iNOS down-regulation on VEGF production  
In stimulated cells, the presence of NO led to a 3-fold increase in VEGF production 
compared with the absence of NO (Figure 6A). In the absence of NO, stimulation did not 
affect VEGF synthesis. Moreover, when NO was produced, stimulation increased VEGF 
production by 1.7-fold. In tumour homogenates, the decreased NO production did not modify 
VEGF expression (Figure 6B). 
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Discussion 
In the present study, a novel tetracycline inducible iNOS expression system was generated 
in order to exclusively investigate the role of tumour cell-derived iNOS on tumour growth and 
angiogenesis. In this system, the expression of antisense iNOS by the tumour cells was 
repressed when doxycycline was added to the cell culture medium or to the drinking water of 
tumour-bearing animals, and hence the expression of iNOS was maintained at basal 
endogenous levels. In the absence of doxycycline, an antisense iNOS RNA was expressed, 
which in turn blocked the expression tumour cell-derived iNOS. Some expression was still 
evident in the micro-environment of these tumours, presumably arising from accessory cells 
from the host such as macrophages, fibroblasts and endothelial cells, known additional 
sources of iNOS.31 MRI was performed in vivo to non-invasively assess tumour vascular 
function, and compared with ex vivo histopathology.  
In designing this Tet-inducible tumour model, we chose an antisense iNOS approach rather 
than an overexpression model, because iNOS overexpression could result in non-
physiological concentrations of NO, which in turn could lead to non-specific effects on both 
tumour and host. For example, high NO concentration could result in accumulation of 
cytotoxic molecules, such as superoxide, hydrogen peroxide, peroxynitrite, and hydrogen 
cyanide.32, 33 Moreover, high concentrations of NO can lead to vascular 'steal' effects, which 
involve the redistribution of blood away from the tumour, as a result of NO-mediated 
systemic vasodilation.34, 35 By using an antisense iNOS approach rather than an 
overexpression genetically modified model, non-specific effects on both tumour and host can 
be avoided. The Tet Off regulation system offers the advantage of using the transfected cells 
themselves as internal controls, as the gene of interest in these cells is silenced in the 
presence of doxycycline.36 Constitutive expressing systems in which the gene of interest is 
always expressed demand the use of mock transfected cells as control, which may lead to 
clonal variation complicating the results.37  
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In our C6 inducible glioma model, suppression of tumour cell-derived NO reduced the 
tumour growth rate. Pharmacological iNOS inhibitors, such as 1400W and BYK191023, have 
been shown to reduce the progression of subcutaneous and intracranial human glioma 
xenografts in mice,8 and systemic iNOS inhibition with L-NAME reduced growth and induced 
significant necrosis in orthotopic C6 rat gliomas.38 Similarly, C6 tumours constitutively 
expressing antisense iNOS grew significantly slower compared with wild type.22 Additionally, 
constitutive expression of iNOS in human DLD1 colon cancer xenografts resulted in 
increased tumour growth.10, 20 Our study suggests that differences in tumour growth between 
wild type and genetically engineered iNOS knockout C6 tumours reported in previous 
studies21, 22 are specifically due to the effects of tumour-derived NO on tumour growth, and 
not a consequence of clonal variation on the growth rates between wild type and transfected 
cells. 
The mechanism(s) by which the expression of iNOS in tumour cells promotes growth is still 
unclear; increased proliferation, enhanced migration and invasion, increased angiogenesis 
due to VEGF upregulation.6, 10, 39 In the present study, the reduced growth observed in NO-
deficient tumours was due neither to changes in the cell’s inherent ability to divide (no 
difference in in vitro growth) nor reduced VEGF production. Tumour VEGF expression was 
similar for NO- and NO+ tumours. Similarly, reduced iNOS expression in C6 cells 
constitutively expressing antisense iNOS did not correlate with decreased VEGF expression 
compared with wild type tumours.22 Since the confounding factor of clonal variability has 
been avoided, our results suggests that in C6 tumours VEGF production is not reliant on the 
production of NO and that NO is involved in VEGF-independent mechanisms enhancing 
tumour growth. 
iNOS activity could promote tumour growth by maintaining tumour blood vessel tone and 
function.2 Cullis et al showed that iNOS overexpression increases tumour growth, 
functionally perfused vasculature and angiogenesis.9 Whittle et al  reported that NOS was 
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expressed in orthotopic C6 rat brain tumours, and that NO-mediated mechanisms 
contributed to regulation of tumour blood flow and vessel dilatation.40 In the same model, 
systemic NOS inhibition with L-NAME caused a greater reduction in tumour blood flow 
compared with normal brain. In a similar C6 model, NOS was found to regulate tumour blood 
flow 41. In a previous study of subcutaneous C6 tumours with limited iNOS expression there 
was reduced tumour growth due to a dysfunctional vascular network and impaired tumour 
perfusion.22 In our C6 inducible model, NO- tumours appeared to have a better vascular 
supply, as indicated by the significantly higher fBV, increased perfusion and higher 
microvessel density, compared with NO+ tumours. However, NO+ tumours were more 
necrotic compared with NO- tumours; hence, the fraction of viable tissue was higher in the 
latter. This is in agreement with a study in GH3 prolactinomas, which showed a correlation 
between low fBV and increased necrosis, as necrotic areas are devoid of blood vessels.42 In 
contrast, in the study by Kostourou et al, NO-deficient tumours, despite their slower growth 
rate, had lower fBV and were more necrotic with less viable tissue compared with wild type 
C6 tumours, while vessel density was similar.22 The present study, by using the Tet Off 
inducible system to manipulate NO production in a single cell line, overcomes the effects of 
clonal variation on tumour vascular characteristics experienced in previous studies, hence 
more accurately provides a measure of how endogenous tumour-derived NO affects growth 
and vascular development. Increased necrosis in our faster-growing NO+ tumours is 
consistent with them outgrowing their blood supply and rate of new vessel development, 
leading to nutrient and oxygen deprivation and ultimately cell death. 
Tumour vascular maturation, manifested by perivascular cell recruitment, can be detected by 
comparing susceptibility MRI in response to hypercapnic gas challenges with carbogen and  
with air-CO2 (95% air and 5% CO2); which utilizes the ability of mature vessels to dilate in 
response to elevated levels of CO2.
43
 In the present study we have used susceptibility MRI in 
response to hypercapnic hyperoxia to assess CO2-reactivity in well vascularised regions 
determined by susceptibility MRI with a blood pool contrast agent. Combining spatial 
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information from both the carbogen breathing response and the measurement of vascular 
volume provides a better assessment of vascular characteristics than do the separate 
measurements.44, 45 We have now demonstrated that in regions of similar vascular volume, 
the NO+ tumours had a greater ∆R2* response to carbogen compared to the NO
- tumours, 
which was correlated with a higher perivascular cell content and fraction of mature vessels. 
Thus, our study suggests a more mature and functional vascularity in the presence of NO 
and highlights the importance of tumour-derived NO in vessel maturation. Studies have 
shown that NO produced by eNOS in vascular endothelial cells plays a crucial role in vessel 
maturation by promoting perivascular cell recruitment. In B16 murine melanomas, reduction 
of NOS expression via NO blockade resulted in decreased perivascular cell coverage.46 
Ischaemic limbs of eNOS–/– mice also presented reduced perivascular cell coverage.47 
However, in our study the effect of NO on vessel maturation is mediated by iNOS, rather 
than eNOS, as NO production was modulated by specifically regulating iNOS expression. 
In conclusion, NO derived from iNOS expressed by tumour cells plays a crucial role in the 
development of our C6 iNOS-inducible tumours, as not only does it promote tumour growth, 
but it is also involved in the recruitment of perivascular cells during the maturation of the 
neovasculature at the later stages of angiogenesis. These findings reinforce the concept of 
iNOS as a target for anti-vascular therapy of cancer. Our study also highlights the ability of 
susceptibility MRI to non-invasively investigate tumour vasculature and detect differences in 
tumour vascular phenotype induced by NO, indicating that a combined fBV and carbogen-
induced ∆R2* analysis may provide a non-invasive biomarker of tumour vascular maturation.  
Page 17 of 30
John Wiley & Sons, Inc.
International Journal of Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
18 
 
Acknowledgements 
This work was supported by a Medical Research Council (MRC) and St. George’s Hospital 
Medical School PhD studentship awarded to EP, the Association for International Cancer 
Research (AICR) (Grant No. 09-0310) and the Biotechnology and Biological Sciences 
Research Council (Grant No. S20430). The authors would like to thank Prof Judith 
Cartwright for providing the original clone for the murine antisense-iNOS, and Glyn Fisher 
and his staff for animal care.  
 
 
 
 
 
 
 
 
 
Page 18 of 30
John Wiley & Sons, Inc.
International Journal of Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
19 
 
References 
  1. Janakiram NB, Rao CV. iNOS-selective inhibitors for cancer prevention: 
promise and progress. Future medicinal chemistry 2012;4: 2193-204. 
 2. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of 
angiogenesis. Proceedings of the National Academy of Sciences of the United States of 
America 1994;91: 4082-5. 
 3. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. 
Nature reviews Cancer 2006;6: 521-34. 
 4. Lechner M, Lirk P, Rieder J. Inducible nitric oxide synthase (iNOS) in tumor 
biology: The two sides of the same coin. Seminars in Cancer Biology 2005;15: 277-89. 
 5. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour 
progression. The lancet oncology 2001;2: 149-56. 
 6. Ambs S, Merriam WG, Bennett WP, Felley-Bosco E, Ogunfusika MO, Oser SM, 
Klein S, Shields PG, Billiar TR, Harris CC. Frequent nitric oxide synthase-2 expression in 
human colon adenomas: implication for tumor angiogenesis and colon cancer progression. 
Cancer Res 1998;58: 334-41. 
 7. Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA. Expression of nitric 
oxide synthase in human central nervous system tumors. Cancer research 1995;55: 727-30. 
 8. Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, Misuraca KL, Lathia 
JD, Forrester MT, Lee J, Stamler JS, Goldman SA, Bredel M, et al. Glioma stem cell 
proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 2011;146: 53-
66. 
 9. Cullis ER, Kalber TL, Ashton SE, Cartwright JE, Griffiths JR, Ryan AJ, Robinson 
SP. Tumour overexpression of inducible nitric oxide synthase (iNOS) increases 
angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent 
ZD6126. Microvascular research 2006;71: 76-84. 
 10. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes 
P, Westmore K, Emson PC, Moncada S. Roles of nitric oxide in tumor growth. Proceedings 
of the National Academy of Sciences of the United States of America 1995;92: 4392-6. 
 11. Coulter JA, Page NL, Worthington J, Robson T, Hirst DG, McCarthy HO. 
Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early 
stage and advanced prostate cancer. The journal of gene medicine 2010;12: 755-65. 
 12. Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, Nathan C, Fidler IJ. 
Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and 
abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 1995;181: 1333-43. 
 13. Pipili-Synetos E, Papageorgiou A, Sakkoula E, Sotiropoulou G, Fotsis T, 
Karakiulakis G, Maragoudakis ME. Inhibition of angiogenesis, tumour growth and metastasis 
by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. Br J Pharmacol 
1995;116: 1829-34. 
 14. Jadeski LC, Lala PK. Nitric oxide synthase inhibition by N(G)-nitro-L-arginine 
methyl ester inhibits tumor-induced angiogenesis in mammary tumors. The American journal 
of pathology 1999;155: 1381-90. 
 15. Konopka TE, Barker JE, Bamford TL, Guida E, Anderson RL, Stewart AG. Nitric 
oxide synthase II gene disruption: implications for tumor growth and vascular endothelial 
growth factor production. Cancer Res 2001;61: 3182-7. 
 16. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy 
for cancer. Br J Cancer 2007;96: 1788-95. 
 17. Malcolm GP, Jodrell DI, MacLellan A, Swaroop GR, Kelly PA, Whittle IR. Effects 
of nitric oxide manipulation on the disposition of platinum in an experimental glioma model. 
Neuroreport 1998;9: 181-5. 
 18. Gratton JP, Lin MI, Yu J, Weiss ED, Jiang ZL, Fairchild TA, Iwakiri Y, Groszmann 
R, Claffey KP, Cheng YC, Sessa WC. Selective inhibition of tumor microvascular 
permeability by cavtratin blocks tumor progression in mice. Cancer cell 2003;4: 31-9. 
Page 19 of 30
John Wiley & Sons, Inc.
International Journal of Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
20 
 
 19. Ng QS, Goh V, Milner J, Stratford MR, Folkes LK, Tozer GM, Saunders MI, 
Hoskin PJ. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a 
phase I study. The lancet oncology 2007;8: 111-8. 
 20. Ambs S, Merriam WG, Ogunfusika MO, Bennett WP, Ishibe N, Hussain SP, 
Tzeng EE, Geller DA, Billiar TR, Harris CC. p53 and vascular endothelial growth factor 
regulate tumor growth of NOS2-expressing human carcinoma cells. Nature medicine 1998;4: 
1371-6. 
 21. Yamaguchi S, Bell HS, Shinoda J, Holmes MC, Wharton SB, Whittle IR. Glioma 
tumourgenicity is decreased by iNOS knockout: experimental studies using the C6 striatal 
implantation glioma model. Br J Neurosurg 2002;16: 567-72. 
 22. Kostourou V, Cartwright JE, Johnstone AP, Boult JK, Cullis ER, Whitley G, 
Robinson SP. The role of tumour-derived iNOS in tumour progression and angiogenesis. Br 
J Cancer 2011;104: 83-90. 
 23. Di Rosa M, Radomski M, Carnuccio R, Moncada S. Glucocorticoids inhibit the 
induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun 
1990;172: 1246-52. 
 24. Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for 
simultaneous detection of nitrate and nitrite. Nitric Oxide 2001;5: 62-71. 
 25. Bradford MM. A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Analytical biochemistry 
1976;72: 248-54. 
 26. Abramovitch R, Frenkiel D, Neeman M. Analysis of subcutaneous angiogenesis 
by gradient echo magnetic resonance imaging. Magnetic resonance in medicine : official 
journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance 
in Medicine 1998;39: 813-24. 
 27. Howe FA, Robinson SP, McIntyre DJ, Stubbs M, Griffiths JR. Issues in flow and 
oxygenation dependent contrast (FLOOD) imaging of tumours. NMR in biomedicine 
2001;14: 497-506. 
 28. Robinson SP, Rodrigues LM, Howe FA, Stubbs M, Griffiths JR. Effects of 
different levels of hypercapnic hyperoxia on tumour R(2)* and arterial blood gases. Magnetic 
resonance imaging 2001;19: 161-6. 
 29. Tropres I, Grimault S, Vaeth A, Grillon E, Julien C, Payen JF, Lamalle L, Decorps 
M. Vessel size imaging. Magnetic resonance in medicine : official journal of the Society of 
Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 2001;45: 
397-408. 
 30. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of 
image analysis. Nature methods 2012;9: 671-5. 
 31. Vannini F, Kashfi K, Nath N. The dual role of iNOS in cancer. Redox biology 
2015;6: 334-43. 
 32. Borutaite V, Budriunaite A, Brown GC. Reversal of nitric oxide-, peroxynitrite- and 
S-nitrosothiol-induced inhibition of mitochondrial respiration or complex I activity by light and 
thiols. Biochimica et biophysica acta 2000;1459: 405-12. 
 33. Lee DH, Pfeifer GP. Mutagenesis induced by the nitric oxide donor sodium 
nitroprusside in mouse cells. Mutagenesis 2007;22: 63-7. 
 34. Jordan BF, Misson P, Demeure R, Baudelet C, Beghein N, Gallez B. Changes in 
tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison 
with carbogen: monitoring by EPR and MRI. International journal of radiation oncology, 
biology, physics 2000;48: 565-70. 
 35. Oronsky BT, Scicinski JJ, Reid T, Knox S. Beyond antiangiogenesis: vascular 
modulation as an anticancer therapy-a review. Translational oncology 2012;5: 133-40. 
 36. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by 
tetracycline-responsive promoters. Proceedings of the National Academy of Sciences of the 
United States of America 1992;89: 5547-51. 
 37. Senner V, Sturm A, Hoess N, Wassmann H, Paulus W. In vivo glioma model 
enabling regulated gene expression. Acta neuropathologica 2000;99: 603-8. 
Page 20 of 30
John Wiley & Sons, Inc.
International Journal of Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
21 
 
 38. Swaroop GR, Kelly PA, Bell HS, Shinoda J, Yamaguchi S, Whittle IR. The effects 
of chronic nitric oxide synthase suppression on glioma pathophysiology. British journal of 
neurosurgery 2000;14: 543-8. 
 39. Jadeski LC, Hum KO, Chakraborty C, Lala PK. Nitric oxide promotes murine 
mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness 
and angiogenesis. International journal of cancer Journal international du cancer 2000;86: 
30-9. 
 40. Whittle IR, Collins F, Kelly PA, Ritchie I, Ironside JW. Nitric oxide synthase is 
expressed in experimental malignant glioma and influences tumour blood flow. Acta 
neurochirurgica 1996;138: 870-5; discussion 5-6. 
 41. Swaroop GR, Malcolm GP, Kelly PA, Ritchie I, Whittle IR. Effects of nitric oxide 
modulation on tumour blood flow and microvascular permeability in C6 glioma. Neuroreport 
1998;9: 2577-81. 
 42. Howe FA, McPhail LD, Griffiths JR, McIntyre DJ, Robinson SP. Vessel size index 
magnetic resonance imaging to monitor the effect of antivascular treatment in a rodent tumor 
model. Int J Radiat Oncol Biol Phys 2008;71: 1470-6. 
 43. Abramovitch R, Dafni H, Smouha E, Benjamin LE, Neeman M. In vivo prediction 
of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: 
magnetic resonance imaging of C6 rat glioma in nude mice. Cancer research 1999;59: 5012-
6. 
 44. Burrell JS, Walker-Samuel S, Baker LC, Boult JK, Jamin Y, Ryan AJ, Waterton 
JC, Halliday J, Robinson SP. Evaluation of novel combined carbogen USPIO (CUSPIO) 
imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 
gliomas. International journal of cancer Journal international du cancer 2012;131: 1854-62. 
 45. Burrell JS, Walker-Samuel S, Baker LC, Boult JK, Ryan AJ, Waterton JC, 
Halliday J, Robinson SP. Investigating temporal fluctuations in tumor vasculature with 
combined carbogen and ultrasmall superparamagnetic iron oxide particle (CUSPIO) 
imaging. Magnetic resonance in medicine : official journal of the Society of Magnetic 
Resonance in Medicine / Society of Magnetic Resonance in Medicine 2011;66: 227-34. 
 46. Kashiwagi S, Izumi Y, Gohongi T, Demou ZN, Xu L, Huang PL, Buerk DG, Munn 
LL, Jain RK, Fukumura D. NO mediates mural cell recruitment and vessel morphogenesis in 
murine melanomas and tissue-engineered blood vessels. The Journal of clinical 
investigation 2005;115: 1816-27. 
 47. Yu J, deMuinck ED, Zhuang Z, Drinane M, Kauser K, Rubanyi GM, Qian HS, 
Murata T, Escalante B, Sessa WC. Endothelial nitric oxide synthase is critical for ischemic 
remodeling, mural cell recruitment, and blood flow reserve. Proceedings of the National 
Academy of Sciences of the United States of America 2005;102: 10999-1004. 
 
 
 
 
 
 
 
 
 
 
Page 21 of 30
John Wiley & Sons, Inc.
International Journal of Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
22 
 
Figure legends  
Figure 1 In vitro characterization of C6 pTet-off asiNOS cells in the presence and 
absence of doxycycline.  
Cells were treated for 4 days with 2 µg/ml doxycycline. For the last 2 days, cells were also 
stimulated with cytokines (10 ng/ml TNF-α, 1000 U/ml IFN-γ) and 5 µg/ml LPS. A: iNOS (131 
kDa) expression determined by western blot. The integrated density of the individual bands 
for iNOS was corrected using α-actin (42 kDa). Results are mean +1 SEM of three separate 
experiments (**P < 0.01). B: Nitrite production. Results are the mean +1 SEM of three 
separate experiments performed in triplicate (***P < 0.001).  
 
Figure 2 In vivo characterization of control and doxycycline treated C6 pTet-off 
asiNOS xenografts.   
Cells (2 x 106) were injected into the flanks of nude mice. Mice were given 0.2 mg/ml 
doxycycline in 5% (w/v) sucrose (+dox, n = 5) or 5% (w/v) sucrose alone (-dox, n = 4) in the 
drinking water ad libitum. A: Western blot of tumour homogenates and the mean box plot 
distributions of the integrated densities of the individual bands for iNOS corrected using α-
actin, showing that doxycycline regulates iNOS expression (*P < 0.05). B: NOx production 
by tumours determined in homogenates. Results are the mean +1 SEM of triplicate 
measurements made from all tumours in each group (*P < 0.05, Unpaired t-test on the 
transformed data (Y=Log(Y)). Note: Logarithmic transformation was used to normalize the 
skewed data. C: Mean tumour growth curves for C6 iNOS-inducible NO- (n = 6) and NO+ (n 
= 5) tumours, showing that reduced iNOS expression delays tumour growth (day 46: *P < 
0.05). 
 
Figure 3 Effects of NO down-regulation on tumour vascular development as 
determined by MRI of C6 pTet-off asiNOS xenografts.  
A: Representative T2-weighted images, parametric maps of baseline R2*air, fractional blood 
volume (fBV) and ∆R2*CB in response to carbogen, from the central tumour slice. ROIs 
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encompassing the whole tumour volume are demarcated on the T2-weighted images. B,C,D: 
Box plot distributions of the median fBV values measured over the whole tumour volume (B), 
and the median fBV values (C) and the median ∆R2*CB values (D) in regions where fBV is 
higher than the median fBV value of all the data, of NO- (n = 4) or NO+ (n = 5) tumours (*P < 
0.05).  
 
Figure 4 Histological assessment of the vasculature of C6 pTet-off asiNOS xenografts 
in the absence or presence of doxycycline.  
A: RGB images are composite images from frozen whole tumour sections stained with the 
perfusion marker Hoechst 33342 and the hypoxia marker pimonidazole. Hoechst 33342 
perfused tumour blood vessels fluoresce blue, and areas of pimonidazole adducts fluoresce 
green. B: H&E-stained sections indicating necrotic regions (arrows). C: RGB images are 
composite images from frozen sections stained with the endothelial cell marker CD31, 
detected using a biotinylated goat anti-rat IgG attached to Fluorescein Avidin D that 
fluoresces green, and the perivascular cell marker α-SMA, detected using an Alexa-546-
conjugated secondary antibody that fluoresces red. Scale bar is 1 mm. 
 
Figure 5 Quantification of histological markers of tumour vasculature for C6 pTet-off 
asiNOS xenografts.  
A: Hoechst 33342 perfused area, B: Pimonidazole adduct area, C: Necrotic area, D: 
Endothelial cell content (CD31 stained area), E: Perivascular cell coverage (α-SMA stained 
area), and F: fraction of mature vessels (α-SMA/CD31 ratio) of C6 iNOS-inducible NO- and 
NO+ tumours. Results are means +1 SEM of three sections per tumour for n = 4 in the NO- 
and n = 5 in the NO+ group (*P < 0.05, **P < 0.01). 
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Figure 6 Investigation of the effect of NO synthesis on VEGF expression in vitro and 
in vivo. 
 A: VEGF production in conditioned medium from C6 pTet-off asiNOS cells treated with 
2µg/ml doxycycline for 5 days.  For the last 3 days, cells were also stimulated with cytokines 
(10 ng/ml TNF-α, 1000 U/ml IFN-γ) and 5 µg/ml LPS. Results are means + 1 SEM of three 
separate experiments in duplicate (*P < 0.05, **P < 0.01). B: VEGF expression in C6 iNOS-
inducible tumour homogenates. Tumours derived from animals provided with drinking water 
containing 0.2 mg/ml doxycycline in 5% (w/v) sucrose (NO+, n = 4) or 5% (w/v) sucrose 
alone (NO-, n = 5). Results are means +1 SEM of triplicate measurements made from all 
tumours in each group.  
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In vitro characterization of C6 pTet-off asiNOS cells in the presence and absence of doxycycline.  
Cells were treated for 4 days with 2 µg/ml doxycycline. For the last 2 days, cells were also stimulated with 
cytokines (10 ng/ml TNF-α, 1000 U/ml IFN-γ) and 5 µg/ml LPS. A: iNOS (131 kDa) expression determined 
by western blot. The integrated density of the individual bands for iNOS was corrected using α-actin (42 
kDa). Results are mean +1 SEM of three separate experiments (**P < 0.01). B: Nitrite production. Results 
are the mean +1 SEM of three separate experiments performed in triplicate (***P< 0.001).  
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In vivo characterization of control and doxycycline treated C6 pTet-off asiNOS xenografts.  
Cells (2 x 106) were injected into the flanks of nude mice. Mice were given 0.2 mg/ml doxycycline in 5% 
(w/v) sucrose (+dox, n = 5) or 5% (w/v) sucrose alone (-dox, n = 4) in the drinking water ad libitum. A: 
Western blot of tumour homogenates and the mean box plot distributions of the integrated densities of the 
individual bands for iNOS corrected using α-actin, showing that doxycycline regulates iNOS expression (*P < 
0.05). B: NOx production by tumours determined in homogenates. Results are the mean +1 SEM of 
triplicate measurements made from all tumours in each group (*P < 0.05, Unpaired t-test on the 
transformed data (Y=Log(Y)). Note: Logarithmic transformation was used to normalize the skewed data. C: 
Mean tumour growth curves for C6 iNOS-inducible NO- (n = 6) and NO+ (n = 5) tumours, showing that 
reduced iNOS expression delays tumour growth (day 46: *P < 0.05).  
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Effects of NO down-regulation on tumour vascular development as determined by MRI of C6 
pTet-off asiNOS xenografts.  
A: Representative T2-weighted images, parametric maps of baseline R2*air, fractional blood volume (fBV) and 
∆R2*CB in response to carbogen, from the central tumour slice. ROIs encompassing the whole tumour 
volume are demarcated on the T2-weighted images. B,C,D: Box plot distributions of the median fBV values 
measured over the whole tumour volume (B), and the median fBV values (C) and the median ∆R2*CB values 
(D) in regions where fBV is higher than the median fBV value of all the data, of NO- (n = 4) or NO+ (n = 5) 
tumours (*P < 0.05).  
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Histological assessment of the vasculature of C6 pTet-off asiNOS xenografts in the absence or 
presence of doxycycline.  
A: RGB images are composite images from frozen whole tumour sections stained with the perfusion marker 
Hoechst 33342 and the hypoxia marker pimonidazole. Hoechst 33342 perfused tumour blood vessels 
fluoresce blue, and areas of pimonidazole adducts fluoresce green. B: H&E-stained sections indicating 
necrotic regions (arrows). C:RGB images are composite images from frozen sections stained with the 
endothelial cell marker CD31, detected using a biotinylated goat anti-rat IgG attached to Fluorescein Avidin 
D that fluoresces green, and the perivascular cell marker α-SMA, detected using an Alexa-546-conjugated 
secondary antibody that fluoresces red. Scale bar is 1 mm.  
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Quantification of histological markers of tumour vasculature for C6 pTet-off asiNOS xenografts.  
A: Hoechst 33342 perfused area, B: Pimonidazole adduct area, C: Necrotic area, D: Endothelial cell content 
(CD31 stained area), E: Perivascular cell coverage (α-SMA stained area), and F: fraction of mature vessels 
(α-SMA/CD31 ratio) of C6 iNOS-inducible NO- and NO+ tumours. Results are means +1 SEM of three 
sections per tumour for n = 4 in the NO- and n = 5 in the NO+ group (*P < 0.05, **P < 0.01).  
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Investigation of the effect of NO synthesis on VEGF expression in vitro and in vivo.  
A: VEGF production in conditioned medium from C6 pTet-off asiNOS cells treated with 2µg/ml doxycycline 
for 5 days.  For the last 3 days, cells were also stimulated with cytokines (10 ng/ml TNF-α, 1000 U/ml IFN-
γ) and 5 µg/ml LPS. Results are means + 1 SEM of three separate experiments in duplicate (*P < 0.05, **P 
< 0.01). B: VEGF expression in C6 iNOS-inducible tumour homogenates. Tumours derived from animals 
provided with drinking water containing 0.2 mg/ml doxycycline in 5% (w/v) sucrose (NO+, n = 4) or 5% 
(w/v) sucrose alone (NO-, n = 5). Results are means +1 SEM of triplicate measurements made from all 
tumours in each group.  
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